Promogran® Prisma Collagen Dressings Puracol® Plus Ag+ MSC8722EP. A6010-A6024 Replicare® Hydrocolloid Exuderm® Satin MSC5444. A6234-A6236 Restore® Wound Cleanser Wound Cleanser Skintegrity® Wound Cleanser MSC6008 N/A Saf-Clens® Wound Cleanser Skintegrity Wound Cleanser MSC6008. N/A Saf-Gel® Hydrogel Skintegrity Hydrogel MSC6102. A6248. PROMOGRAN Prisma Wound Balancing Collagen Dressings. Primary dressing transforms into conformable, biodegradable gel in the presence of exudate to help maintain physiologically moist microenvironment at wound surface. Ionically bound silver helps provide barrier for the reduction of bacterial growth of common pathogens like Pseudomonas.
Prisma Migrate
Prisma Migrate uses Prisma schema changes to automatically generate fully customizable
database schema migrations
Auto-generated
Migrations are automatically generated so you don't have to write the SQL by hand.
Deterministic/Repeatable
Migrate generates SQL migrations, ensuring migrations will always result in same database schema across environments.
Customizable
Generated SQL migrations can be fully customized giving you full control over the exact changes.
Iteration
Fast in Development
Prototype fast without migrations
While prototyping you can create the database schema quickly using the prisma db push command without creating migrations.
Integrated seeding
Quickly seed your database with data by defining a seed script in JavaScript, TypeScript or Shell.
Smart problem resolution
Migrate detects database schema drift and assists you in resolving them.
Deployment
Reliable in Production
Dedicated production workflows
Migrate supports dedicated workflows for carrying out migrations safely in production.
CI/CD Integration
Migrate can be integrated into CI/CD pipelines, e.g. GitHub Actions, to automate applying migrations before deployment.
Conflict detection and resolution
Prisma Health
Migrate keeps track of applied migrations and provides tools to detect and resolve conflicts and drifts between migrations and the database schema.
Seamless integration with Prisma Client
When using Prisma Migrate with Prisma Client, schema changes are type checked in your application code. This eliminates errors that arise when database schema changes require changes to the application code.
Declarative data modelling
Prisma Migrate generates migrations based on changes in the Prisma schema – a human-readable declarative definition of your database schema. This allows you to focus on your desired database schema rather than the steps to get there.
Version control for your database
With Prisma Migrate, generated migrations are tracked in your Git repository, allowing you to make changes to your database schema in tandem with your application code.
Streamlined collaboration
Prisma Migrate enables smooth collaboration with workflows that make it easy for teams to review and test database schema changes before going to production.
Bring your own project
Prisma Migrate can be adopted in any existing project that uses PostgreSQL, MySQL, MariaDB, or SQLite.
Products
Prisma ClientPrisma MigratePrisma StudioPrisma 1 CloudPrisma Data PlatformProduct RoadmapResources
DocsGet StartedAPI ReferenceExamplesHow to GraphQLData GuideEnterprise EventPrisma With
Prisma with Next.jsPrisma with GraphQLPrisma with ApolloPrisma with NestJSPrisma with ExpressPrisma with hapiCommunity
Prisma AmbassadorMeet the CommunityPrisma DaySlackGitHubDiscussionsGraphQL MeetupTypeScript MeetupAdvanced TypeScript TrickeryConnect Dev AfricaCompany
AboutJobs We're hiring!CausesBlogTerms & PrivacyHTML SitemapNewsletter
Stay up to date with the latest features and changes to Prisma
Find Us
Prisma © 2018-2021.
Made with ❤️ in Berlin and worldwide
Dear Editor,
In Turkish Otorhinolaryngology publications reviews are often written in the form of an account, and systematic reviews and meta analyses are rarely performed (–). A systematic approach to a review, however, will minimize bias and maximize its contribution to science. Including meta-analysis in a review will carry the publication to the highest level of evidence. This will also significantly increase the citability of the report.
Mychart Prisma
As the Turkish Archives of Otorhinolaryngology is the scientific open access journal of our society, this scientific letter aims to reach our colleagues who plan on writing reviews in the field of otorhinolaryngology with the use of PRISMA guidelines for the purpose of standardizing systematic review writing.
According to the common opinion, a review type article is the interpretation, synthesis and assessment of the scientific reports and studies printed in scientific publications by authors experienced in the area (5). Reviews written with an analogous approach cannot go beyond an account of what has been already done: They cover a wide range of topics within a given subject; may be useful in understanding new concepts, but are rarely comprehensive; rarely give details about the methods; are likely to be written in line with the opinions of the author; quality differences between the studies are rarely considered; and as a result, can be misinterpreted and lead to inadvertent bias.
To avoid these issues in systematic review writing, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) group, which mainly consists of Cochrane authors, has developed the PRISMA guidelines in 2009 (). A systematic review will extensively scan all reports published on the subject to find the answers to a clearly defined research question, and to that end will use various inclusion and exclusion criteria to identify the reports to be included in the review, and then synthesize the findings. Using statistical methods for the interpretation of the results implies a systematic review containing meta-analysis ().
The PRISMA guidelines consist of a four-phase flow diagram and a 27-item checklist. The flow diagram describes the identification, screening, eligibility and inclusion criteria of the reports that fall under the scope of a review. The checklist includes a 27-item recommendation list on topics such as title, abstract, introduction, methods, results, discussion and financing. With this flow diagram and checklist, PRISMA items serve as a guide for authors, reviewers and editors.
PRISMA extensions can be reached at their website: www.prisma-statement.org (7). The Turkish translations of the flow diagram and the checklist can also be found here. The website also includes a scientific report authored by the PRISMA group that gives examples to a systematic review in line with the guidelines, as well as detailed explanations and descriptions (). All content related to the PRISMA guidelines are open access for the purposes of disseminating its utilization.
Full compliance with the checklist items will facilitate clarity and transparency in reporting; and thereby enable a structured report that well-defines the study question, clearly states its title and objectives, benefits from a comprehensive strategy for identifying all relevant study reports, clearly and justifiably indicates inclusion and exclusion criteria, critically and accurately prioritizes the reviewed study reports, provides a clear analysis of the eligible study reports based on qualitative and—where applicable in relation to the data—quantitative (meta-analysis) content.
As stated in the ‘Instructions for Authors’ page of your journal, the PRISMA items are the recommended reporting method to be adopted in order to avoid the basic mistakes in systematic review and meta-analysis reports. I believe that wider adoption of these guidelines in our country will significantly contribute to the otorhinolaryngology reports published in Turkey.
Acknowledgements
I would like to thank Prof. Cenk Ecevit, MD for raising my awareness on this issue, hence causing me to write this scientific letter.
Footnotes
This study was presented at the A to Z Scientific Study Planning, Writing and Publishing Processes Meeting in Health Sciences, January 9 2019, Sivas, Turkey.
Peer-review: Externally peer-reviewed.
Conflict of Interest: The author has no conflicts of interest to declare.
Financial Disclosure: The author declared that this study has received no financial support.